[go: up one dir, main page]

AR043370A1 - Composiciones farmaceuticas de administracion oral y metodos para evitar la interaccion alimento -droga - Google Patents

Composiciones farmaceuticas de administracion oral y metodos para evitar la interaccion alimento -droga

Info

Publication number
AR043370A1
AR043370A1 ARP040100567A ARP040100567A AR043370A1 AR 043370 A1 AR043370 A1 AR 043370A1 AR P040100567 A ARP040100567 A AR P040100567A AR P040100567 A ARP040100567 A AR P040100567A AR 043370 A1 AR043370 A1 AR 043370A1
Authority
AR
Argentina
Prior art keywords
methods
pharmaceutical compositions
oral administration
drug interaction
drug
Prior art date
Application number
ARP040100567A
Other languages
English (en)
Inventor
Ae Ri Kim
Kwang-Hyung Cho
Ji-Hye Lee
Sun Hwa Lee
Ho Jun Kim
Han-Joo Maeng
Hee Dong Park
Tae-Hun Kim
Bong-Chan Kim
Sung-Ji Kim
Kyo-Seok Choo
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of AR043370A1 publication Critical patent/AR043370A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65H—HANDLING THIN OR FILAMENTARY MATERIAL, e.g. SHEETS, WEBS, CABLES
    • B65H35/00—Delivering articles from cutting or line-perforating machines; Article or web delivery apparatus incorporating cutting or line-perforating devices, e.g. adhesive tape dispensers
    • B65H35/0006—Article or web delivery apparatus incorporating cutting or line-perforating devices
    • B65H35/0073—Details
    • B65H35/008—Arrangements or adaptations of cutting devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65H—HANDLING THIN OR FILAMENTARY MATERIAL, e.g. SHEETS, WEBS, CABLES
    • B65H35/00—Delivering articles from cutting or line-perforating machines; Article or web delivery apparatus incorporating cutting or line-perforating devices, e.g. adhesive tape dispensers
    • B65H35/0006—Article or web delivery apparatus incorporating cutting or line-perforating devices
    • B65H35/002—Hand-held or table apparatus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65H—HANDLING THIN OR FILAMENTARY MATERIAL, e.g. SHEETS, WEBS, CABLES
    • B65H2301/00—Handling processes for sheets or webs
    • B65H2301/50—Auxiliary process performed during handling process
    • B65H2301/51—Modifying a characteristic of handled material
    • B65H2301/515—Cutting handled material
    • B65H2301/5153—Details of cutting means
    • B65H2301/51532—Blade cutter, e.g. single blade cutter

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composición farmacéutica de administración oral de un inhibidor de trombina entre otros que previene una disminución en la biodisponibilidad de una droga luego de la ingesta de alimentos, que comprende: i) dicha droga, y ii) un polímero bioadhesivo farmacéuticamente aceptable, para prevenir la disminución en el grado de absorción de la droga debido a una interacción con enzimas digestivas o ingredientes alimenticios luego de la ingesta de alimentos.
ARP040100567A 2003-02-24 2004-02-24 Composiciones farmaceuticas de administracion oral y metodos para evitar la interaccion alimento -droga AR043370A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20030011392 2003-02-24

Publications (1)

Publication Number Publication Date
AR043370A1 true AR043370A1 (es) 2005-07-27

Family

ID=32906553

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100567A AR043370A1 (es) 2003-02-24 2004-02-24 Composiciones farmaceuticas de administracion oral y metodos para evitar la interaccion alimento -droga

Country Status (5)

Country Link
US (1) US20040229821A1 (es)
KR (1) KR20040076203A (es)
AR (1) AR043370A1 (es)
TW (1) TW200420304A (es)
WO (1) WO2004073747A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7167686B2 (en) * 2002-01-25 2007-01-23 Qualcomm Incorporated Wireless communications transceiver: transmitter using a harmonic rejection mixer and an RF output offset phase-locked loop in a two-step up-conversion architecture and receiver using direct conversion architecture
US7097967B2 (en) * 2002-10-24 2006-08-29 Lg Life Sciences Ltd. Method of predicting drug-food interaction
EP1891089B1 (en) * 2005-06-02 2014-11-05 Merck Sharp & Dohme Corp. HCV protease inhibitors in combination with food
CA2657269A1 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New indications for direct thrombin inhibitors
BRPI0715492A2 (pt) * 2006-07-17 2013-03-19 Boehringer Ingelheim Int uso de inibidores diretos de trombina
CA2662542A1 (en) * 2006-09-12 2008-03-20 Glaxo Group Limited Pharmaceutical composition comprising a plurality of mini-tablets comprising a factor xa inhibitor
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
CN110302168A (zh) * 2013-01-28 2019-10-08 万平 定位速释生物粘附剂及其制备方法和应用
US9596622B2 (en) * 2014-01-31 2017-03-14 Cable Television Laboratories, Inc. Mesh networking of access points for load balancing
GB2542064B (en) * 2015-01-20 2020-11-18 Univ California Unit aerosol doses for anticoagulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5294615A (en) * 1993-04-29 1994-03-15 Abbott Laboratories Terazosin polymorph and pharmaceutical composition
JPH11510514A (ja) * 1996-04-10 1999-09-14 メルク エンド カンパニー インコーポレーテッド 経口被覆活性薬物
GB9910773D0 (en) * 1999-05-11 1999-07-07 West Pharm Serv Drug Res Ltd Novel single unit coated dosage forms that can be used to minimise the effect of food on the absorption of drugs from the gastrointestinal tract
US6338857B1 (en) * 2000-05-26 2002-01-15 Pharma Pass Llc Sustained release carbamazepine pharmaceutical composition free of food effect and a method for alleviating food effect in drug release
US6368628B1 (en) * 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect

Also Published As

Publication number Publication date
WO2004073747A1 (en) 2004-09-02
KR20040076203A (ko) 2004-08-31
US20040229821A1 (en) 2004-11-18
TW200420304A (en) 2004-10-16

Similar Documents

Publication Publication Date Title
CO5170471A1 (es) Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio
NO330947B1 (no) Anvendelse av farmasoytiske sammensetninger som inneholder okskarbazepin, i fastende tilstand
AR038527A1 (es) Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo
NO20045140L (no) Blandinger og fremgangsmate for transmukosal legemiddelavlevering og kryobeskyttelse
TW200505498A (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
DK1471890T3 (da) Farmaceutisk doseringsform til mukös afgivelse
EP2444072A3 (en) Non-mucoadhesive film dosage forms
AR013506A1 (es) Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
EA200801926A1 (ru) Таблетки парацетамола с быстрым высвобождением
UY25544A1 (es) Forma de dosificación de nefazodona
DE60313359D1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
AR109644A2 (es) Pradofloxacina y composición farmacéutica para el tratamiento sistémico de enfermedades bacterianas en la cavidad bucal
UY27929A1 (es) Composiciones farmaceuticas de farmacos semiordenados y polimeros
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
AR043370A1 (es) Composiciones farmaceuticas de administracion oral y metodos para evitar la interaccion alimento -droga
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
CO5580741A2 (es) Composicion farmaceutica que comprende un agonista de receptor de 5ht1
AR042543A1 (es) Composiciones de anti-histaminicos, descongestivos y drogas anti-inflamatorias no esteroides
DK1517677T3 (da) Poppende oral administrationsform
AR030957A1 (es) Composiciones de analgesico y glucosamina
MXPA06000332A (es) Nueva composicion farmaceutica solida que comprende amisulprida.
DE60205905D1 (de) Pharmazeutische zusammensetzung zur orale verabreichung mit verbesserter bioverfügbarkeit
PE20030830A1 (es) Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faringea

Legal Events

Date Code Title Description
FA Abandonment or withdrawal